Skip to main content
SpringerLink
Log in

The Role of Tacrolimus Ointment in Atopic Dermatitis

  • Chapter
Tacrolimus Ointment

Abstract

Sometimes exciting and important changes occur that comprise a wholly new therapeutic approach, resulting in a sudden and marked improvement within a field of medicine. Throughout the history of medicine it has been these periods of rapid change, the quantum shifts in which one paradigm is superseded by a new and more effective approach, that have marked the course of progress.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bekersky I, Fitzsimmons W, Tanase A et al. (2001) Nondinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 44: S17–27

    Article  PubMed  CAS  Google Scholar 

  2. Bode HH (1980) Dwarfism following long-term topical corticosteroid therapy. JAMA 244: 813–814

    Article  PubMed  CAS  Google Scholar 

  3. Bridgett C, Noren P, Staughton R (1996) Atopic skin disease. A manual for practitioners. Wrightson Biomedical Publishing, Petersfield

    Google Scholar 

  4. Caro I, Gordon KB, West DP et al. (2002) Long-term safety of topically applied tacrolimus ointment in adult patients with atopic dermatitis. 60th Annual meeting of the American Academy of Dermatology, New Orleans, USA, February 22–27, Poster 111

    Google Scholar 

  5. Charman CR, Morris AD, Williams HC (2000) Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 142: 931–936

    Article  PubMed  CAS  Google Scholar 

  6. Drake L, Prendergast M, Maher R et al. (2001) The impact of tacrolimus ointment on health related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 44: S65–72

    Article  PubMed  CAS  Google Scholar 

  7. Dumont FJ (2000) FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem 7: 731–748

    Article  PubMed  CAS  Google Scholar 

  8. Finlay AY (2001) Quality of life in atopic dermatitis. J Am Acad Dermatol 45: S64–66

    Article  PubMed  CAS  Google Scholar 

  9. Fukaya M (2000) Why do patients with atopic dermatitis refuse to apply topical corticosteroids? Dermatology 201: 242–245

    Article  PubMed  CAS  Google Scholar 

  10. Goerz G, Lehmann P (1991) Topical treatment with corticosteroids. In: Ruzicka T, Ring J, Przybilia B (eds) Hand-book of atopic eczema. Springer, Berlin Heidelberg New York Tokyo, pp 375–390

    Chapter  Google Scholar 

  11. Hanifin JM, Ling MR, Langley R et al. (2001) Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part 1, efficacy. J Am Acad Dermatol 44: S28–38

    Article  PubMed  CAS  Google Scholar 

  12. Hanifin J, Leung D, Palier A, Rico MJ (2003) Tacrolimus ointment monotherapy is safe and effective for the long-term treatment [more than 3 years] of atopic dermatitis in pediatric patients. 59th Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI), Denver, USA, March 7–12, abstract

    Google Scholar 

  13. Hill CJ, Rosenberg A Jr (1978) Adverse effects from topical steroids. Cutis 21: 624–628

    PubMed  CAS  Google Scholar 

  14. Hoare C, Li Wan Po A, Williams H (2000) Systematic review of treatments for atopic eczema. Health Technol Assess 4: 1–189

    PubMed  CAS  Google Scholar 

  15. Horn JT, Estridge T (1993) FK506 and rapamycin modulate the functional activities of human peripheral blood eosinophils. Clin Immunol Immunopathol 68: 293–300

    Article  Google Scholar 

  16. Hughes J, Rustin M (1997) Corticosteroids. Clin Dermatol 15: 715–721

    Article  PubMed  CAS  Google Scholar 

  17. Kang S, Lucky AW, Pariser D et al. (2001) Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 44: S58–64

    Article  PubMed  CAS  Google Scholar 

  18. Kohyama T, Takizawa H Kawasaki S et al. (1999) A potent immunosuppressant FK506 inhibits IL-8 expression in human eosinophils. Mol Cell Biol Res Commun 1: 72–77

    Article  PubMed  CAS  Google Scholar 

  19. Koo J, Abramovits W, Fivenson D, Horn T, Rico MJ, Jaracz E (2002) The experience of tacrolimus ointment in adult atopic dermatitis patients: the results of two large open-label studies. 60th Annual meeting of the American Academy of Dermatology, New Orleans, USA, February 22–27, Poster 105

    Google Scholar 

  20. Leung DYM (1998) Molecular basis of allergic diseases. Mol Genet Metab 63: 157–167

    Article  PubMed  CAS  Google Scholar 

  21. Leung DYM (2000) Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 105: 860–876

    Article  PubMed  CAS  Google Scholar 

  22. Leung DYM, Soter NA (2001) Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 44: S1–12

    Article  PubMed  CAS  Google Scholar 

  23. Leung D, Eichenfield L, Fleischer A et al. (2002) Use of tacrolimus ointment in atopic dermatitis patients with limited disease. 60th Annual meeting of the American Academy of Dermatology, New Orleans, USA, February 22–27, Poster 102

    Google Scholar 

  24. Liu J, Albers MW, Wandless TJ et al. (1992) Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry 31: 3896–3901

    Article  PubMed  CAS  Google Scholar 

  25. Lübbe J, Pournaras CC, Saurat JH (2000) Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment. Dermatology 201: 249–251

    Article  PubMed  Google Scholar 

  26. McLean C, Lobo R, Brazier D (1995) Cataracts, glaucoma, femoral avascular necrosis caused by topical corticosteroid ointment. Lancet 346: 1298

    PubMed  Google Scholar 

  27. Nakagawa H, Etoh T, Ishibashi Y (1994) Tacrolimus ointment for atopic dermatitis. Lancet 344: 883

    Article  PubMed  CAS  Google Scholar 

  28. Naylor M, Elmets C, Rico JM (2002) Treatment with topical tacrolimus is not associated with an increase in non-melanoma skin cancers. 60th Annual meeting of the American Academy of Dermatology, New Orleans, USA, February 22–27, Poster 18

    Google Scholar 

  29. Ngheim P, Pearson G, Langley R (2002) Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 46: 228–241

    Article  Google Scholar 

  30. Palier A, Eichenfield LF, Leung DYM et al. (2001) A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 44: S47–57

    Article  Google Scholar 

  31. Palier AS, Hanifin J, Eichenfield L, Rico MJ, Ayes M (2002) Long-term safety of topically applied tacrolimus ointment in pediatrie patients 2–15 years of age with atopic dermatitis. 60th Annual meeting of the American Academy of Dermatology, New Orleans, USA, February 22–27, Poster 104

    Google Scholar 

  32. Panhans-Groß A, Novak N, Kraft S, Bieber T (2001) Human epidermal Langerhans cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 107: 345–352

    Article  PubMed  Google Scholar 

  33. de Paulis A, Cirillo R, Ciccarelli A, Condorelli M, Marone G (1991) FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. J Immunol 146: 2374–2381

    PubMed  Google Scholar 

  34. de Paulis A, Stellato C, Cirillo R, Ciccarelli A, Oriente A, Marone G (1992) Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol 99: 723–728

    Article  PubMed  Google Scholar 

  35. Prose NS, Fleischer A, Koo J, Smith ML, Rico MJ, Zheng S (2002) Safety and efficacy of topical tacrolimus ointment in young children age 2–6 years of age with atopic dermatitis. 60th Annual meeting of the American Academy of Dermatology, New Orleans, USA, February 22–27, Poster 103

    Google Scholar 

  36. de Prost Y, Bodemer C, Teillac D (1989) Double-blind randomized placebo-controlled trial of local cyclosporine in atopic dermatitis. Arch Dermatol 125: 570

    Article  PubMed  Google Scholar 

  37. Protopic (tacrolimus) ointment full prescribing information. Deerfield, Ill: Fujisawa Healthcare Inc., 2002

    Google Scholar 

  38. Quielle C, Pommarede R, Saurat JH (1984) Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol 1: 246–253

    Article  Google Scholar 

  39. Reitamo S, Rissanen J, Remitz A et al. (1998) Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 111: 396–398

    Article  PubMed  CAS  Google Scholar 

  40. Reitamo S, Wollenberg A, Schöpf E et al. (2000) Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 136: 999–1006

    Article  CAS  Google Scholar 

  41. Reitamo S, Rustin M, Ruzicka T et al. (2002) Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 109: 547–555

    Article  PubMed  CAS  Google Scholar 

  42. Reitamo S, van Leent EJM, Ho V et al. for the European/Canadian Tacrolimus Ointment Study Group (2002) Efficacy and safety of tacrolimus ointment compared with hydrocortisone acetate in children with atopic dermatitis. J Allergy Clin Immunol 109: 539–546

    Article  PubMed  CAS  Google Scholar 

  43. Reitamo S (2003) 0.1% tacrolimus ointment is significantly more efficaceous than a steroid regimen in adults with moderate to severe atopic dermatitis. European Academy of Dermatology and Venerology Spring Symposium, Malta.

    Google Scholar 

  44. Remitz A, Kyllönen H, Granlund H, Reitamo S (2001) Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol 107: 196–197

    Article  PubMed  CAS  Google Scholar 

  45. Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C (1982) Cushing’s syndrome after topical application of corticosteroid. Am J Dis Child 136: 247–275

    Google Scholar 

  46. Sengoku T, Kishi S, Sakuma S, Ohkubo Y, Goto T (2000) FK506 inhibition of histamine release and cytokine production by mast cells and basophils. Int J Immunopharmacol 22: 189–201

    Article  PubMed  CAS  Google Scholar 

  47. Sheehan MP, Rustin MH, Atherton DJ et al. (1992) Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis. Lancet 340: 13–17

    Article  PubMed  CAS  Google Scholar 

  48. Sheu HM, Chang CH (1991) Alterations in water content of the stratum corneum following long-term topical corticosteroids. J Formos Med Assoc 90: 664–669

    PubMed  CAS  Google Scholar 

  49. Soter NA, Fleischer AB Jr, Webster GF et al. (2001) Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 44: S39–46

    Article  PubMed  CAS  Google Scholar 

  50. Tocci MJ, Matkovich DA, Collier KA et al. (1989) The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 143: 718–726

    PubMed  CAS  Google Scholar 

  51. Undre NA, Stevenson P, Schafer A (1999) Pharmacokinetics of tacrolimus: clinically relevant aspects. Transplant Proc 31: 21S–24S

    Article  PubMed  CAS  Google Scholar 

  52. du Vivier A, Stoughton RB (1975) Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol 111: 581–583

    Article  PubMed  Google Scholar 

  53. Wollenberg A, Sharma S, von Bubnoff D, Geiger E, Haberstok J, Bieber T (2001) Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 107: 519–525

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. S. Reitamo
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätsklinikum Düsseldorf Hautklinik, Heinrich-Heine-Universität, Moorenstraße 5, 40225, Düsseldorf, Germany

    Thomas Ruzicka

  2. Hospital for Skin and Allergic Diseases, Department of Dermatology, Helsinki University Central Hospital, Meilahdentie 2, 00250, Helsinki, Finland

    Sakari Reitamo

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Reitamo, S. (2004). The Role of Tacrolimus Ointment in Atopic Dermatitis. In: Ruzicka, T., Reitamo, S. (eds) Tacrolimus Ointment. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10209-1_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10209-1_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-10211-4

  • Online ISBN: 978-3-662-10209-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation